摘要
目的探讨乳腺癌术后应用紫杉醇联合吡柔比星化学治疗(简称化疗)的临床疗效及护理措施。方法选择2015年2月至2016年7月收治的90例乳腺癌术后应用紫杉醇联合吡柔比星化疗患者,随机分为两组,各45例。对照组给予常规护理方法,观察组给予优质护理措施。结果观察组患者乳腺癌病灶稳定率为95.56%,高于对照组的82.22%(P<0.05);观察组化疗不良反应(消化道反应、骨髓抑制、神经毒性)发生率低于对照组(P<0.05);护理后观察组生活质量综合评定量表总分、焦虑自评量表评分及抑郁自评量表评分等情绪状态指标改善幅度更大(P<0.05)。结论乳腺癌术后应用紫杉醇联合吡柔比星化疗的临床疗效确切,辅以优质护理措施,可减轻患者的不良情绪,减少化疗不良反应的发生,提升患者生存质量,值得临床推广。
Objective To investigate the clinical efficacy and nursing measures of paclitaxel combined with pirarubicin in treating breast cancer after operation.Methods A total of 90 patients with breast cancer treated with paclitaxel combined with pirarubicin chemotherapy from February 2015 to July 2016 were selected and randomly divided into two groups,45 cases in each group.The control group was given routine nursing,and the observation group was given high quality nursing intervention.Results The stability rate of breast cancer in observation group was 95.56%,which was higher than 82.22% in control group(P 〈 0.05).The incidence rate of adverse reactions(digestive tract reaction,myelosuppression,neurotoxicity) in the observation group was lower than that in the control group(P 〈 0.05).After nursing,the QOL total score,SAS score and SDS score and other emotional status indicators in the observation group improved more obviously(P 〈 0.05).Conclusion Paclitaxel combined with pirarubicin in treating breast cancer after operation has good effect,with high quality nursing,it can reduce the unhealthy emotions of patients,reduce the occurrence of adverse reactions,and improve the quality of life of patients,it is worthy of clinical promotion.
作者
孟燕
任艳蕊
Meng Yan Ren Yanrui(The First People's Hospital of Jingzhou, Jingzhou, Hubei, China 43400)
出处
《中国药业》
CAS
2017年第15期68-70,共3页
China Pharmaceuticals
关键词
乳腺癌
紫杉醇
吡柔比星
化学治疗
临床疗效
护理措施
breast cancer
paclitaxel
pirarubicin
chemotherapy
clinical effect
nursing measure